Innovent Biologics (HKSE:01801) PB Ratio

: 3.90 (As of Today)

View and export this data going back to 2018. Start your Free Trial

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-19), Innovent Biologics's share price is HK$33.20. Innovent Biologics's Book Value per Share for the quarter that ended in Jun. 2023 was HK$8.51. Hence, Innovent Biologics's PB Ratio of today is 3.90.

Good Sign:

Innovent Biologics Inc stock PB Ratio (=3.87) is close to 1-year low of 3.79

The historical rank and industry rank for Innovent Biologics's PB Ratio or its related term are showing as below:

HKSE:01801' s PB Ratio Range Over the Past 10 Years
Min: 2.15 Med: 5.98 Max: 17.4
Current: 3.87

During the past 8 years, Innovent Biologics's highest PB Ratio was 17.40. The lowest was 2.15. And the median was 5.98.

HKSE:01801's PB Ratio is ranked worse than
68.52% of 1312 companies
in the Biotechnology industry
Industry Median: 2.385 vs HKSE:01801: 3.87

During the past 12 months, Innovent Biologics's average Book Value Per Share Growth Rate was -0.10% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 23.00% per year.

During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Innovent Biologics was 27.90% per year. The lowest was 23.00% per year. And the median was 25.45% per year.

Back to Basics: PB Ratio

Innovent Biologics PB Ratio Historical Data

The historical data trend for Innovent Biologics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovent Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

PB Ratio

6.33

11.16

5.58

4.29

5.02

Innovent Biologics Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
PB Ratio											5.58	4.56	4.29	3.87	5.02

Competitive Comparison

For the Biotechnology subindustry, Innovent Biologics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovent Biologics PB Ratio Distribution

For the Biotechnology industry and Healthcare sector, Innovent Biologics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Innovent Biologics's PB Ratio falls into.

Innovent Biologics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Innovent Biologics's PB Ratio for today is calculated as follows:

PB Ratio	=	Share Price	/	Book Value per Share (Q: Jun. 2023)
	=	33.20	/	8.509
	=	3.90

It can also be calculated from the numbers for the whole company:

PB Ratio

Market Cap

(Total Stockholders Equity

Preferred Stock)

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Innovent Biologics (HKSE:01801) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.

Innovent Biologics PB Ratio Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovent Biologics (HKSE:01801) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (HKSE:01801) » Definitions » PB Ratio

Comparable Companies

Traded in Other Exchanges

IVBXF:USA IVBIY:USA 6IB:Germany

Address

168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.innoventbio.com

Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.

Innovent Biologics (HKSE:01801) Headlines

No Headlines